Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Reiterated by Cantor Fitzgerald

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Monday, Benzinga reports. They currently have a $10.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 40.06% from the stock’s previous close.

Separately, HC Wainwright reissued a “buy” rating and issued a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Trading Up 0.1 %

Shares of AUPH opened at $7.14 on Monday. The company has a current ratio of 5.33, a quick ratio of 4.82 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $1.02 billion, a P/E ratio of -16.60 and a beta of 1.44. Aurinia Pharmaceuticals has a 1-year low of $4.71 and a 1-year high of $10.05. The business’s 50-day moving average price is $6.12 and its 200 day moving average price is $5.57.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share for the quarter, meeting the consensus estimate of $0.01. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. The company had revenue of $57.10 million for the quarter, compared to analyst estimates of $54.25 million. During the same period last year, the company earned ($0.08) earnings per share. The business’s revenue was up 37.6% compared to the same quarter last year. Analysts expect that Aurinia Pharmaceuticals will post 0.13 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Scott Michael Habig sold 18,249 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total transaction of $96,902.19. Following the completion of the transaction, the insider now directly owns 456,338 shares in the company, valued at $2,423,154.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of AUPH. Armistice Capital LLC grew its holdings in Aurinia Pharmaceuticals by 57.7% in the fourth quarter. Armistice Capital LLC now owns 9,536,000 shares of the biotechnology company’s stock worth $85,729,000 after purchasing an additional 3,488,000 shares during the period. Goldman Sachs Group Inc. increased its position in Aurinia Pharmaceuticals by 39.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,048,456 shares of the biotechnology company’s stock valued at $18,416,000 after buying an additional 576,120 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in Aurinia Pharmaceuticals during the 2nd quarter worth approximately $1,713,000. Campbell & CO Investment Adviser LLC bought a new position in Aurinia Pharmaceuticals in the fourth quarter worth approximately $2,089,000. Finally, GSA Capital Partners LLP grew its stake in Aurinia Pharmaceuticals by 196.1% in the first quarter. GSA Capital Partners LLP now owns 349,204 shares of the biotechnology company’s stock valued at $1,750,000 after acquiring an additional 231,260 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.